These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 36307004)

  • 41. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density.
    Genant HK; Engelke K; Hanley DA; Brown JP; Omizo M; Bone HG; Kivitz AJ; Fuerst T; Wang H; Austin M; Libanati C
    Bone; 2010 Jul; 47(1):131-9. PubMed ID: 20399288
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of Denosumab on Femoral Periprosthetic BMD and Early Femoral Stem Subsidence in Postmenopausal Women Undergoing Cementless Total Hip Arthroplasty.
    Aro HT; Nazari-Farsani S; Vuopio M; Löyttyniemi E; Mattila K
    JBMR Plus; 2019 Oct; 3(10):e10217. PubMed ID: 31687650
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial.
    Leder BZ; Tsai JN; Neer RM; Uihlein AV; Wallace PM; Burnett-Bowie SA
    J Clin Densitom; 2016; 19(3):346-51. PubMed ID: 26900146
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial.
    Miyauchi A; Hamaya E; Yang W; Nishi K; Libanati C; Tolman C; Shimauchi J
    J Bone Miner Metab; 2021 Mar; 39(2):278-288. PubMed ID: 33057807
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of sequential therapy from short-term teriparatide to denosumab compared with denosumab alone in patients with osteoporotic hip fracture: a 1-year follow-up study.
    Park CH; Yoo JI; Choi CH; Suh YS
    BMC Musculoskelet Disord; 2020 Nov; 21(1):751. PubMed ID: 33189148
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study.
    Bolognese MA; Teglbjærg CS; Zanchetta JR; Lippuner K; McClung MR; Brandi ML; Høiseth A; Lakatos P; Moffett AH; Lorenc RS; Wang A; Libanati C
    J Clin Densitom; 2013; 16(2):147-53. PubMed ID: 22521543
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial.
    Langdahl BL; Teglbjærg CS; Ho PR; Chapurlat R; Czerwinski E; Kendler DL; Reginster JY; Kivitz A; Lewiecki EM; Miller PD; Bolognese MA; McClung MR; Bone HG; Ljunggren Ö; Abrahamsen B; Gruntmanis U; Yang YC; Wagman RB; Mirza F; Siddhanti S; Orwoll E
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1335-42. PubMed ID: 25607608
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: a preliminary report.
    Diamond T; Ng AT; Levy S; Magarey C; Smart R
    Osteoporos Int; 1996; 6(4):329-33. PubMed ID: 8883124
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
    Brown JP; Roux C; Ho PR; Bolognese MA; Hall J; Bone HG; Bonnick S; van den Bergh JP; Ferreira I; Dakin P; Wagman RB; Recknor C
    Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomized, open-label, controlled trial of monthly oral minodronate or semiannual subcutaneous injection of denosumab for bone loss by androgen deprivation in Asian men with prostate cancer: the PRevention of Osteopenia with Minodronate And DEnosumab (PROMADE) study.
    Yoshida T; Kinoshita H; Taniguchi H; Yanishi M; Sugi M; Matsuda T
    Osteoporos Int; 2020 Jul; 31(7):1251-1259. PubMed ID: 31993719
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Switching to Denosumab or Bisphosphonates After Completion of Teriparatide Treatment in Women With Severe Postmenopausal Osteoporosis.
    Kocjan T; Rajic AS; Janez A; Vidmar G; Orehek N; Marc J; Ostanek B
    Endocr Pract; 2021 Sep; 27(9):941-947. PubMed ID: 34111556
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
    Zanchetta MB; Boailchuk J; Massari F; Silveira F; Bogado C; Zanchetta JR
    Osteoporos Int; 2018 Jan; 29(1):41-47. PubMed ID: 28975362
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Operative intervention for primary hyperparathyroidism offers greater bone recovery in patients with sporadic disease than in those with multiple endocrine neoplasia type 1-related hyperparathyroidism.
    Silva AM; Vodopivec D; Christakis I; Lyons G; Wei Q; Waguespack SG; Petak SM; Grubbs E; Lee JE; Perrier N
    Surgery; 2017 Jan; 161(1):107-115. PubMed ID: 27842919
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
    Nakatsukasa K; Koyama H; Ouchi Y; Ono H; Sakaguchi K; Matsuda T; Kato M; Ishikawa T; Yamada K; Yoshimura M; Koizumi K; Sakurai T; Shigematsu H; Takahashi S; Taira S; Suzuki M; Narui K; Niikura N; Hasegawa Y; Miura D; Konishi E; Taguchi T;
    Breast Cancer; 2019 Jan; 26(1):106-112. PubMed ID: 30054855
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bone Mineral Density After Transitioning From Denosumab to Alendronate.
    Kendler D; Chines A; Clark P; Ebeling PR; McClung M; Rhee Y; Huang S; Stad RK
    J Clin Endocrinol Metab; 2020 Mar; 105(3):e255-64. PubMed ID: 31665314
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis.
    McClung MR; Zanchetta JR; Høiseth A; Kendler DL; Yuen CK; Brown JP; Stonkus S; Goemaere S; Recknor C; Woodson GC; Bolognese MA; Franek E; Brandi ML; Wang A; Libanati C
    J Clin Densitom; 2013; 16(2):250-6. PubMed ID: 22572531
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study.
    Gu J; Zhang H; Xue Q; Wang L; Cheng Z; Zhang Y; Li Q; Yuan L; Li Y; Dong J; Huo Y; Tang X; Hu L; Wang X; Hua F; Shen L; Cheng J; Zhou H; Xu Y; Yang T; Wang C; Xu J; Shen J; Zhang Y; Zhang X; Hong D; Guan X; Xiao X; Wang G; Liu Y; Fu L; Chen J; Cheng X; Ding Y; Liu L; Yao Q; Zhang X; Li L; Zhang P; Deng C; Jiang C; You L; Wang K; Zhang S; Xiao J; Liu W; Du X; Shang X; Pan T; Lei C; Guo S; Zhang Z
    J Orthop Translat; 2023 Jan; 38():117-125. PubMed ID: 36381249
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.
    Saag KG; Wagman RB; Geusens P; Adachi JD; Messina OD; Emkey R; Chapurlat R; Wang A; Pannacciulli N; Lems WF
    Lancet Diabetes Endocrinol; 2018 Jun; 6(6):445-454. PubMed ID: 29631782
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of previous treatment with bisphosphonate and renal impairment on the response to denosumab in osteoporosis: a 'real-life' study.
    Fraser TR; Flogaitis I; Moore AE; Hampson G
    J Endocrinol Invest; 2020 Apr; 43(4):469-475. PubMed ID: 31664706
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
    Leder BZ; Tsai JN; Uihlein AV; Burnett-Bowie SA; Zhu Y; Foley K; Lee H; Neer RM
    J Clin Endocrinol Metab; 2014 May; 99(5):1694-700. PubMed ID: 24517156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.